Morishima Yasuo, Morishima Satoko, Murata Makoto, Arima Nobuyoshi, Uchida Naoyuki, Sugio Yasuhiro, Takahashi Satoshi, Matsuhashi Yoshiko, Onizuka Makoto, Eto Tetsuya, Nagafuji Koji, Onishi Yasushi, Inoue Masami, Atsuta Yoshiko, Fukuda Takahiro, Ichinohe Tatsuo, Kato Shunichi, Kanda Junya
Central Japan Cord Blood Bank, Seto, Japan; Department of Hematology and Oncology, Nakagami Hospital, Okinawa, Japan; Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, Japan.
Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.
Biol Blood Marrow Transplant. 2020 Jan;26(1):132-138. doi: 10.1016/j.bbmt.2019.09.009. Epub 2019 Sep 12.
Induced pluripotent stem cells (iPSCs) have been applied to clinical regenerative cell therapy. Recently, an iPSC banking system to collect HLA haplotype (HP) homozygous (homo) cells for iPSC transplantation in allogeneic settings was proposed, and tissue transplantation generated from iPSC through banking has just began. We analyzed 5017 single cord blood transplantation (CBT) pairs with HLA-A, -B, -C, -DRB1 allele typing data and found 39 donor HLA homo donor to patient HLA heterozygous (hetero) pairs. Of note, all 39 HLA homo to hetero pairs engrafted neutrophils, except 1 early death pair, and all 30 assessable pairs engrafted platelets. Acute graft-versus-host disease (GVHD) grades II to IV and grades III to IV occurred in 17 and 3 of 38 assessable pairs, respectively. Competing risk regression analysis revealed a favorable risk of neutrophil engraftment and higher risk of acute GVHD compared with HLA-matched CBTs. Thirty-seven of 39 homo to hetero pairs had conserved extended HLA HPs (HP-1, n = 18; HP-2, n = 8; HP-3, n = 7; HP-4, n = 4; HP-5, n = 1) that were ethnicity-specific, and at least 1 of 2 patient HLA-A, -B, -C, and -DRB1 alleles in each locus were invariably shared with the same donor HP in 35 pairs. These findings confirmed our preliminary results with 6 HLA homo CBTs, and a trend of high incidence of acute GVHD was newly observed. Importantly, they imply the possibility that HLA-homo iPSC transplantation provides favorable engraftment and accordingly imply the merit of banking iPSC with homozygous major conserved extended HLA HPs.
诱导多能干细胞(iPSC)已应用于临床再生细胞治疗。最近,有人提出了一种iPSC库系统,用于收集HLA单倍型(HP)纯合(homo)细胞,以便在同种异体环境中进行iPSC移植,并且通过该库系统由iPSC产生的组织移植才刚刚开始。我们分析了5017对具有HLA-A、-B、-C、-DRB1等位基因分型数据的单份脐血移植(CBT),发现了39对供体HLA纯合而患者HLA杂合(hetero)的配对。值得注意的是,除了1对早期死亡的配对外,所有39对HLA纯合与杂合配对的中性粒细胞均成功植入,并且所有30对可评估配对的血小板均成功植入。在38对可评估配对中,分别有17对和3对发生了II至IV级和III至IV级急性移植物抗宿主病(GVHD)。竞争风险回归分析显示,与HLA匹配的CBT相比,中性粒细胞植入的风险较低,而急性GVHD的风险较高。39对纯合与杂合配对中有37对具有保守的扩展HLA单倍型(HP-1,n = 18;HP-2,n = 8;HP-3,n = 7;HP-4,n = 4;HP-5,n = 1),这些单倍型具有种族特异性,并且在35对配对中,每个位点的2个患者HLA-A、-B、-C和-DRB1等位基因中至少有1个与同一供体HP始终相同。这些发现证实了我们对6例HLA纯合CBT的初步结果,并且新观察到了急性GVHD高发生率的趋势。重要的是,它们意味着HLA纯合iPSC移植提供良好植入的可能性,因此意味着储存具有纯合主要保守扩展HLA单倍型的iPSC的优点。